Omnicell (NASDAQ:OMCL) EVP Sells $217,180.50 in Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Corey Manley sold 5,025 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the transaction, the executive vice president directly owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Omnicell Stock Performance

NASDAQ OMCL opened at $43.76 on Friday. The firm’s fifty day moving average price is $37.90 and its two-hundred day moving average price is $40.75. The stock has a market cap of $1.99 billion, a PE ratio of 99.46, a PEG ratio of 1.16 and a beta of 0.96. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50. Omnicell, Inc. has a fifty-two week low of $26.84 and a fifty-two week high of $55.00.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. During the same period in the prior year, the company earned $0.26 EPS. Omnicell’s revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, equities analysts expect that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Institutional Trading of Omnicell

Institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. bought a new position in Omnicell during the 2nd quarter worth approximately $26,000. First Horizon Corp bought a new position in Omnicell during the third quarter worth $31,000. Clearstead Advisors LLC lifted its holdings in Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after buying an additional 1,218 shares during the period. Kemnay Advisory Services Inc. bought a new stake in Omnicell during the fourth quarter valued at $58,000. Finally, Parkside Financial Bank & Trust boosted its position in Omnicell by 1,708.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after acquiring an additional 1,264 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

OMCL has been the topic of several research reports. Wells Fargo & Company boosted their price target on Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Thursday, April 23rd. Zacks Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. KeyCorp upped their price target on shares of Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a research report on Tuesday, April 28th. Finally, Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $59.86.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.